HALOZYME THERAPEUTICS, INC.

Biological Products, (No Diagnostic Substances)·SAN DIEGO, CA·FY end 12/31·CIK 1159036

CEO Pay Ratio

—

Helen I. Torley

CEO Total Comp

$23.2M

Helen I. Torley

Median Employee

$231,329

Revenue

$1.4B

FY 2025

Net Income

$316.9M

FY 2025

Free Cash Flow

$644.6M

FY 2025

Net Margin

22.7%

Insider Net (180d)

-$25.2M

0 buys / 48 sales

CEO Pay Accountability

CEO comp as % of net income

7.31%

For every $1,000 of profit, $73.11 flows to the CEO.

CEO comp as % of buybacks

6.77%

CEO comp equals 67.7‰ of cash returned to shareholders via buybacks.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$1.4B	$1.0B	$829.3M	$660.1M	$443.3M
Gross Profit	—	—	—	—	—	—
Operating Income	$469.0M	$551.5M	$337.6M	$267.5M	$275.9M
Net Income	$316.9M	$444.1M	$281.6M	$202.1M	$402.7M
Operating CF	$651.6M	$479.1M	$388.6M	$240.1M	$299.4M
Capex	$7.0M	$10.7M	$15.3M	$4.8M	$1.5M
Free Cash Flow	$644.6M	$468.4M	$373.3M	$235.3M	$298.0M
Buybacks	$342.4M	$250.0M	$402.4M	$109.8M	$150.0M
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	33.6%	54.3%	40.7%	40.5%	62.2%
Net Margin	22.7%	43.7%	34.0%	30.6%	90.8%
FCF Margin	46.2%	46.1%	45.0%	35.6%	67.2%
R&D / Revenue	—	7.8%	9.2%	10.1%	8.0%
Effective Tax	32.1%	20.3%	19.2%	18.8%	62.0%
Debt / Equity	87.79	8.28	35.78	17.58	7.99
Buybacks / FCF	53.1%	53.4%	107.8%	46.7%	50.3%

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Helen I. TorleyPresident and Chief Executive Officer	$1.0M	$19.4M	$1.7M	$1.1M	$18.6K	$23.2M
Nicole LaBrosseSenior Vice President, Chief Financial Officer	$604.2K	$3.0M	$525.0K	$462.2K	$12.3K	$4.6M
Mark SnyderSenior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary	$619.0K	$3.0M	$525.0K	$394.6K	$17.8K	$4.5M
Cortney Caudill	$561.0K	$1.7M	$512.5K	$382.5K	$9.2K	$3.2M
Michael J. LaBarreFormer Senior Vice President, Chief Technical Officer	$120.3K	$1.6M	$276.4K	—	$90.2K	$2.1M